EP227: What Should Pharma Be Doing Right Now About the HHS Proposal to Effectively Curtail PBM Rebates?, With Kuo Tong, Managing Director at Navigant
Episode Description
What Should Pharma Be Doing Right Now About the HHS Proposal to Curtail PBM Rebates? With Kuo Tong (EP227)
How the HHS Rebate Rule Could Reshape Pharma's Relationship With Insurers. Episode 227.
The Department of Health and Human Services has proposed effectively curtailing pharma's ability to pay pharmacy benefit manager (PBM) rebates — and while the impact on patient premiums and drug costs is its own conversation, this episode focuses on what it means for pharmaceutical companies themselves. Stacey Richter talks with Kuo Tong, managing director in the life sciences practice at Navigant, about how pharma's interactions with and reimbursement from insurance companies could change if the rule goes into effect.
WHAT YOU'LL LEARN
✅ How the drug-buying transaction actually works between pharma companies and insurance companies today
✅ Whether pharma's reimbursement relationships with insurers will meaningfully change once the HHS rebate rule takes effect
✅ What pharma companies could and should be doing right now to prepare for a smoother transition into a new contracting model
✅ Kuo Tong's perspective from advising pharma on reimbursement strategy at Navigant
WHY THIS MATTERS
Regulatory proposals like the HHS rebate rule can reshape entire contracting relationships overnight, and pharma companies that wait to react instead of preparing risk getting caught flat-footed. Kuo Tong's insight gives pharma leaders a head start on what a post-rebate contracting model with insurers might actually look like.
=== LINKS ===
🔗 Show Notes with all mentioned links: Episode Page
✉️ Enjoy this podcast? Subscribe to the free weekly newsletter
🫙 Support the podcast with a small donation to the Tip Jar
🎤 Listen on Apple Podcasts
🎤 Listen on Spotify
📺 Subscribe to our YouTube channel
=== CONNECT WITH THE RHV TEAM ===
Proudly Supported by
